NICE | pharmaphorum

Skip to main content

Friday 5 June 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

NICE

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Debates & Insight

Market access webinar Widescreen size NEW v6

Sponsored

Available on demand: Cancer Treatment Access: Strategy, Appr...

Available on demand: A one-hour live debate on Cancer Treatment Access: Right Strategy, Right Approach, Right Outcomes.

News

iStock_67821339_MEDIUM 1

NICE recommends BMS melanoma combination

NICE makes swift decision on skin cancer treatment.

News

Matty

Father petitions NHS to fund kidney drug for son

But NHS refuses £340,000 a year treatment.

News

NICE rejects Janssen's CLL drug

Drug may be paid for by Cancer Drugs Fund

Articles

Microscope

NICE and Highly Specialised Technologies: three years on

Leela Barham examines the process for the appraisal of Highly Specialised Technologies.

News

NHS

NHS under fire for delaying access to rare disease cholester...

Pharma concerned by fairness and transparency of NHS England's Prioritisation Framework

Load more results

Editor's Picks

Servier wagers $2.65bn on Edgewise muscular dystrophy drug

ASCO26: AZ triplet makes waves in frontline liver cancer

ASCO26: Big win for Erleada in perioperative prostate cancer

Lilly licenses Hanmi GLP-2 drug in $1.26bn deal

First human trial backs AI-designed 'universal' vaccine

News

Roche's LightCycler PCR test

Roche develops Bundibugyo Ebola test in six days

A PCR diagnostic developed by Roche for the Bundibugyo form of Ebola is being offered to health systems at the front lines of the current outbreak.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company